학술논문

Sex-biased T cell exhaustion drives differential immune responses in glioblastoma
Document Type
article
Source
Cancer Discovery. 13(9)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Immunology
Rare Diseases
Stem Cell Research - Nonembryonic - Human
Brain Cancer
Vaccine Related
Brain Disorders
Neurosciences
Stem Cell Research
Cancer
Clinical Research
Immunization
Genetics
Male
Female
Mice
Animals
Glioblastoma
T-Cell Exhaustion
CD8-Positive T-Lymphocytes
Immunotherapy
Immunity
Brain Neoplasms
Tumor Microenvironment
Biochemistry and cell biology
Oncology and carcinogenesis
Language
Abstract
Sex differences in glioblastoma (GBM) incidence and outcome are well recognized, and emerging evidence suggests that these extend to genetic/epigenetic and cellular differences, including immune responses. However, the mechanisms driving immunologic sex differences are not fully understood. Here, we demonstrate that T cells play a critical role in driving GBM sex differences. Male mice exhibited accelerated tumor growth, with decreased frequency and increased exhaustion of CD8+ T cells in the tumor. Furthermore, a higher frequency of progenitor exhausted T cells was found in males, with improved responsiveness to anti-PD-1 treatment. Moreover, increased T-cell exhaustion was observed in male GBM patients. Bone marrow chimera and adoptive transfer models indicated that T cell-mediated tumor control was predominantly regulated in a cell-intrinsic manner, partially mediated by the X chromosome inactivation escape gene Kdm6a. These findings demonstrate that sex-biased predetermined behavior of T cells is critical for inducing sex differences in GBM progression and immunotherapy response.SignificanceImmunotherapies in patients with GBM have been unsuccessful due to a variety of factors, including the highly immunosuppressive tumor microenvironment in GBM. This study demonstrates that sex-biased T-cell behaviors are predominantly intrinsically regulated, further suggesting sex-specific approaches can be leveraged to potentially improve the therapeutic efficacy of immunotherapy in GBM. See related commentary by Alspach, p. 1966. This article is featured in Selected Articles from This Issue, p. 1949.